IP Library › Granted Patent US 9,790,277

Granted Patent B2

US 9,790,277 · App. 14/654,109 · Granted Oct 17, 2017

Anti-H7CR antibodies

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,790,277
App. No.: 14/654,109
Granted: Oct 17, 2017
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Antibodies and humanized variants thereof and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, H7CR, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.

Claims (65)

1. A humanized antibody or an antigen-binding fragment thereof that specifically binds to human H7CR, comprising:

(A) (1) a light chain variable region having the amino acid sequence of any of SEQ ID NOS: 17-22; and

(2) a heavy chain variable region having the amino acid sequence of any of SEQ ID NOS: 23-28; or

(B) (1) a light chain variable region having the amino acid sequence of any of SEQ ID NOS: 33-38; and

(2) a heavy chain variable region having the amino acid sequence of any of SEQ ID NOS: 39-44.

2. The antibody or an antigen binding fragment thereof of claim 1 , wherein the H7CR which is specifically bound is:

(A) arrayed on the surface of a live cell; or

(B) expressed at an endogenous concentration.

3. The antibody or an antigen binding fragment thereof of claim 2 , wherein said live cell is a T cell, an NK cell, or a plasmacytoid dendritic cell.

4. The antibody or an antigen binding fragment thereof of claim 1 , wherein the binding of the antibody or the antigen binding fragment thereof to H7CR does not block a binding interaction of B7-H7 and H7CR.

5. The antibody or an antigen binding fragment thereof of claim 1 , wherein the antibody or an antigen binding fragment thereof modulates or agonizes H7CR activity.

6. The antibody or an antigen binding fragment thereof of claim 1 , wherein said antibody is a bispecific or multispecific antibody.

7. The antibody or an antigen binding fragment thereof of claim 1 , wherein said antibody or an antigen binding fragment thereof is detectably labeled or comprises a conjugated toxin, drug, receptor, enzyme, receptor ligand.

8. A pharmaceutical composition comprising a therapeutically effective amount of the antibody or an antigen binding fragment thereof of claim 1 , and a physiologically acceptable carrier or excipient.

9. A method for enhancing an immune response in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 8 .

10. The method of claim 9 , wherein said subject has cancer.

11. The method of claim 9 , wherein said subject has an infectious disease.

12. The method of claim 11 , wherein said infectious disease is a chronic viral disease.

13. The method of claim 9 , wherein said pharmaceutical composition agonizes an H7CR function.

14. The antigen-binding fragment of the anti-H7CR antibody of claim 1 , wherein the antigen-binding fragment specifically binds to human H7CR as antigen.

15. The antigen-binding antibody fragment of claim 14 , wherein the antigen-binding fragment specifically binds to human H7CR which is:

(A) arrayed on the surface of a live cell; or

(B) expressed at an endogenous concentration.

16. The antigen-binding antibody fragment of claim 15 , wherein said live cell is a T cell, an NK cell, or a plasmacytoid dendritic cell.

17. The antigen-binding antibody fragment of claim 14 , wherein the binding of the antigen-binding fragment to H7CR does not block a binding interaction of B7-H7 and H7CR.

18. The antigen-binding antibody fragment of claim 14 , which is an antigen-binding fragment of a bispecific or a multispecific antibody.

19. An antigen-binding antibody fragment of a humanized anti-H7CR antibody that specifically binds to human H7CR as antigen, wherein the antigen-binding fragment comprises six CDRs, which comprise:

(A) three light chain CDRs having SEQ ID NOS: 29, 32, 45 and three heavy chain CDRs having SEQ ID NOS: 49, 52, and 56;

(B) three light chain CDRs having SEQ ID NOS: 30, 32, 46 and three heavy chain CDRs having SEQ ID NOS: 50, 53, and 57; or

20. The antigen-binding antibody fragment of claim 19 , which is an antigen-binding fragment of a bispecific or multispecific antibody.

21. The antigen-binding antibody fragment of claim 19 , which is detectably labeled or comprises a conjugated toxin, drug, receptor, enzyme, or receptor ligand.

22. A pharmaceutical composition comprising a therapeutically effective amount of the antigen-binding fragment of an anti-H7CR antibody of claim 14 , and a physiologically acceptable carrier or excipient.

23. A method for enhancing an immune response in a subject in need thereof, the method comprising: administering to said subject a therapeutically effective amount of the pharmaceutical composition of claim 22 .

24. The method of claim 23 , wherein said subject has cancer.

25. The method of claim 23 , wherein said subject has an infectious disease.

26. The method of claim 25 , wherein said infectious disease is a chronic viral disease.

27. The method of claim 23 , wherein said pharmaceutical composition agonizes an H7CR function.

28. An antigen-binding fragment of an anti-H7CR antibody that specifically binds to human H7CR, wherein said antigen-binding fragment comprises:

(A) (1) a light chain variable region having the amino acid sequence of SEQ ID NO: 5; and

(2) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 6;

(B) (1) a light chain variable region having the amino acid sequence of SEQ ID NO: 7; and

(2) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 8; or

(2) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 10.

29. A humanized antibody or an antigen-binding fragment thereof that specifically binds to human H7CR, comprising:

(1) a light chain variable region comprising amino acid sequence SEQ ID NO: 17 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 23;

(2) a light chain variable region comprising amino acid sequence SEQ ID NO: 17 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 24;

(3) a light chain variable region comprising amino acid sequence SEQ ID NO: 17 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 25;

(4) a light chain variable region comprising amino acid sequence SEQ ID NO: 17 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 26;

(5) a light chain variable region comprising amino acid sequence SEQ ID NO: 17 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 27;

(6) a light chain variable region comprising amino acid sequence SEQ ID NO: 17 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 28;

(7) a light chain variable region comprising amino acid sequence SEQ ID NO: 18 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 24;

(8) a light chain variable region comprising amino acid sequence SEQ ID NO: 18 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 25;

(9) a light chain variable region comprising amino acid sequence SEQ ID NO: 18 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 27;

(10) a light chain variable region comprising amino acid sequence SEQ ID NO: 18 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 28;

(11) a light chain variable region comprising amino acid sequence SEQ ID NO: 19 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 24;

(12) a light chain variable region comprising amino acid sequence SEQ ID NO: 19 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 25;

(13) a light chain variable region comprising amino acid sequence SEQ ID NO: 19 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 27; or

(14) a light chain variable region comprising amino acid sequence SEQ ID NO: 19 and a heavy chain variable region comprising amino acid sequence SEQ ID NO: 28.

30. A humanized antibody or an antigen binding fragment of an antibody that specifically binds a human H7CR, wherein the antibody or the antigen-binding fragment comprises a light chain variable region that comprises a light chain CDR1 of SEQ ID NO: 29, a light chain CDR2 of SEQ ID NO: 32 and a light chain CDR3 of SEQ ID NO: 45; and a heavy chain variable region that comprises a heavy chain CDR1 of SEQ ID NO: 49; a heavy chain CDR2 of SEQ ID NO: 52 and a heavy chain CDR3 of SEQ ID NO: 56.

31. The antibody or an antigen binding fragment thereof of claim 30 , which is a bi specific or multi specific antibody.

32. The antibody or an antigen binding fragment thereof of claim 30 , which is detectably labeled or comprises a conjugated toxin, drug, receptor, enzyme, or receptor ligand.

33. The antibody or an antigen binding fragment thereof of claim 30 , wherein the binding of the antibody or the antigen binding fragment thereof to H7CR does not block a binding interaction of B7-H7 and H7CR.

34. A humanized antibody or an antigen binding fragment thereof that specifically binds to human H7CR, wherein said antibody or an antigen-binding fragment thereof comprises a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 31, a light chain CDR2 of SEQ ID NO: 32, and a light chain CDR3 of SEQ ID NO: 48 and a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 51, a heavy chain CDR2 of SEQ ID NO: 55 and a heavy chain CDR3 of SEQ ID NO: 59.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2015

From: AMPLIMMUNE, INC.

To: MEDIMMUNE, LLC

Reel/Frame 036377/0556 →